HAEMATOLOGICAL CANCER The rule of three in AML induction-is cladribine the answer?

被引：10

作者：

Appelbaum, Frederick R. ^{[1
]}

机构：

[1] Univ Washington, Div Clin Res, Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2012年 / 9卷 / 07期

关键词：

ACUTE MYELOID-LEUKEMIA;

D O I：

10.1038/nrclinonc.2012.98

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In a randomized phase III trial of induction therapy in adult acute myeloid leukaemia, the addition of cladribine, but not fludarabine, to daunorubicin and cytarabine seemed to improve complete response rates and overall survival. However, serious methodological problems make it difficult to estimate the actual clinical importance of the result. © 2012 Macmillan Publishers Limited. All rights reserved.

引用

页码：376 / 377

页数：2

共 10 条

[1]

Appelbaum F. R., 2008, CLIN ONCOLOGY, P2215

[2] Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial [J].

Burnett, Alan K. ;

Hills, Robert K. ;

Milligan, Donald ;

Kjeldsen, Lars ;

Kell, Jonathan ;

Russell, Nigel H. ;

Yin, John A. L. ;

Hunter, Ann ;

Goldstone, Anthony H. ;

Wheatley, Keith .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04) :369-377

[3] Anthracycline Dose Intensification in Acute Myeloid Leukemia [J].

Fernandez, Hugo F. ;

Sun, Zhuoxin ;

Yao, Xiaopan ;

Litzow, Mark R. ;

Luger, Selina M. ;

Paietta, Elisabeth M. ;

Racevskis, Janis ;

Dewald, Gordon W. ;

Ketterling, Rhett P. ;

Bennett, John M. ;

Rowe, Jacob M. ;

Lazarus, Hillard M. ;

Tallman, Martin S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (13) :1249-1259

[4] Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: Pharmacokinetic, pharmacodynamic, and molecular interactions [J].

Gandhi, V ;

Estey, E ;

Keating, MJ ;

Chucrallah, A ;

Plunkett, W .

BLOOD, 1996, 87 (01) :256-264

[5] Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study [J].

Holowiecki, J ;

Grosicki, S ;

Robak, T ;

Kyrcz-Krzemien, S ;

Giebel, S ;

Hellmann, A ;

Skotnicki, A ;

Jedrzejczak, WW ;

Konopka, L ;

Kuliczkowski, K ;

Zdziarska, B ;

Dmoszynska, A ;

Marianska, B ;

Pluta, A ;

Zawilska, K ;

Komarnicki, M ;

Kloczko, J ;

Sulek, K ;

Haus, O ;

Stella-Holowiecka, B ;

Baran, W ;

Jakubas, B ;

Paluszewska, M ;

Wierzbowska, A ;

Kielbinski, M ;

Jagoda, K .

LEUKEMIA, 2004, 18 (05) :989-997

[6]

Holowiecki J, J CLIN ONCOL

[7] Is a nadir bone marrow required and, if so, what to do with residual disease? [J].

Luger, Selina M. .

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2011, 24 (04) :527-532

[8] Acute Myeloid Leukemia [J].

O'Donnell, Margaret R. ;

Abboud, Camille N. ;

Altman, Jessica ;

Appelbaum, Frederick R. ;

Coutre, Steven E. ;

Damon, Lloyd E. ;

Foran, James M. ;

Goorha, Salil ;

Maness, Lori J. ;

Marcucci, Guido ;

Maslak, Peter ;

Millenson, Michael M. ;

Moore, Joseph O. ;

Ravandi, Farhad ;

Shami, Paul J. ;

Smith, B. Douglas ;

Stone, Richard M. ;

Strickland, Stephen A. ;

Tallman, Martin S. ;

Wang, Eunice S. .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2011, 9 (03) :280-317

[9] Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study [J].

Ohtake, Shigeki ;

Miyawaki, Shuichi ;

Fujita, Hiroyuki ;

Kiyoi, Hitoshi ;

Shinagawa, Katsuji ;

Usui, Noriko ;

Okumura, Hirokazu ;

Miyamura, Koichi ;

Nakaseko, Chiaki ;

Miyazaki, Yasushi ;

Fujieda, Atsushi ;

Nagai, Tadashi ;

Yamane, Takahisa ;

Taniwaki, Masafumi ;

Takahashi, Masatomo ;

Yagasaki, Fumiharu ;

Kimura, Yukihiko ;

Asou, Norio ;

Sakamaki, Hisashi ;

Handa, Hiroshi ;

Honda, Sumihisa ;

Ohnishi, Kazunori ;

Naoe, Tomoki ;

Ohno, Ryuzo .

BLOOD, 2011, 117 (08) :2358-2365

[10]

PETERSDORF S, 2009, BLOOD, V114, pA790

← 1 →